Cryoport (CYRX) Q4 2024 earnings summary

Executive summary

• FY 2024 revenue reached $228.4 million, with Q4 revenue at $59.5 million, meeting expectations despite macroeconomic headwinds.

• Life sciences services expanded, with double-digit growth in biostorage and bioservices, now 67% of total revenue.

• Supported a record 701 clinical trials globally, including 81 in phase III, and increased commercial programs from 14 to 19.

• Maintains a global platform with 50+ facilities in 17 countries and over 3,000 clients.

• Cost reduction and capital realignment improved Q4 gross margin to 45.8% from 40.6% year-over-year.

Financial highlights

• FY 2024 revenue was $228.4 million, with Q4 revenue at $59.5 million, up 4% year-over-year.

• Commercial cell and gene therapy revenue grew 20% year-over-year to $26 million, with Q4 up 37% year-over-year.

• Life sciences services revenue rose 6.6% to $153.7 million; products revenue fell 16.2% to $74.7 million for FY 2024.

• Gross margin improved to 45.8% in Q4 2024 from 40.6% in Q4 2023; FY 2024 gross margin was 43.6%.

• Cash and short-term investments totaled $262 million at year-end.

Outlook and guidance

• FY 2025 revenue guidance is $240–$250 million, with expectations for positive adjusted EBITDA.

• Anticipate another record year for commercial revenue and strong new clinical trial acquisition.

• Project up to 23 BLA/MMA filings in 2025, up from 11 in 2024.

• Expects continued growth in services and ongoing softness in product sales.

• Plans to complete cost reduction and capital realignment strategies by year-end.